These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 29466057)

  • 1. ZOLEDRONIC ACID VERSUS ALENDRONATE IN THE TREATMENT OF CHILDREN WITH OSTEOGENESIS IMPERFECTA: A 2-YEAR CLINICAL STUDY.
    Lv F; Liu Y; Xu X; Song Y; Li L; Jiang Y; Wang O; Xia W; Xing X
    Endocr Pract; 2018 Feb; 24(2):179-188. PubMed ID: 29466057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. THE CLINICAL CHARACTERISTICS AND EFFICACY OF BISPHOSPHONATES IN AUDLT PATIENTS WITH OSTEOGENESIS IMPERGECTA.
    Xu XJ; Ma DD; Lv F; Wang JY; Liu Y; Xia WB; Jiang Y; Wang O; Xing XP; Yu W; Li M
    Endocr Pract; 2016 Nov; 22(11):1267-1276. PubMed ID: 27482615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
    Orwoll ES; Miller PD; Adachi JD; Brown J; Adler RA; Kendler D; Bucci-Rechtweg C; Readie A; Mesenbrink P; Weinstein RS
    J Bone Miner Res; 2010 Oct; 25(10):2239-50. PubMed ID: 20499357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Bisphosphonates on Osteoporosis Induced by Duchenne Muscular Dystrophy: A Prospective Study.
    Zheng WB; Dai Y; Hu J; Zhao DC; Wang O; Jiang Y; Xia WB; Xing XP; Li M
    Endocr Pract; 2020 Dec; 26(12):1477-1485. PubMed ID: 33471740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EFFECTS OF LONG-TERM ALENDRONATE TREATMENT ON A LARGE SAMPLE OF PEDIATRIC PATIENTS WITH OSTEOGENESIS IMPERFECTA.
    Lv F; Liu Y; Xu X; Wang J; Ma D; Jiang Y; Wang O; Xia W; Xing X; Yu W; Li M
    Endocr Pract; 2016 Dec; 22(12):1369-1376. PubMed ID: 27482608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta.
    Barros ER; Saraiva GL; de Oliveira TP; Lazaretti-Castro M
    J Pediatr Endocrinol Metab; 2012; 25(5-6):485-91. PubMed ID: 22876543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density.
    Saag K; Lindsay R; Kriegman A; Beamer E; Zhou W
    Bone; 2007 May; 40(5):1238-43. PubMed ID: 17347063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study.
    Tutaworn T; Nieves JW; Wang Z; Levin JE; Yoo JE; Lane JM
    Osteoporos Int; 2023 Mar; 34(3):573-584. PubMed ID: 36602607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study.
    Ward LM; Rauch F; Whyte MP; D'Astous J; Gates PE; Grogan D; Lester EL; McCall RE; Pressly TA; Sanders JO; Smith PA; Steiner RD; Sullivan E; Tyerman G; Smith-Wright DL; Verbruggen N; Heyden N; Lombardi A; Glorieux FH
    J Clin Endocrinol Metab; 2011 Feb; 96(2):355-64. PubMed ID: 21106710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship of Pathogenic Mutations and Responses to Zoledronic Acid in a Cohort of Osteogenesis Imperfecta Children.
    Sun L; Hu J; Liu J; Zhang Q; Wang O; Jiang Y; Xia W; Xing X; Li M
    J Clin Endocrinol Metab; 2022 Aug; 107(9):2571-2579. PubMed ID: 35727737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral bisphosphonate treatment for osteogenesis imperfecta--an Indian perspective.
    Shah I; Johari A
    Ann Trop Paediatr; 2007 Mar; 27(1):39-43. PubMed ID: 17469731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous zoledronic acid and oral alendronate in patients with a low trauma fracture: experience from an osteoporosis clinic.
    Craig SJ; Youssef PP; Vaile JH; Sullivan L; Bleasel JF
    Intern Med J; 2011 Feb; 41(2):186-90. PubMed ID: 20214696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta.
    DiMeglio LA; Peacock M
    J Bone Miner Res; 2006 Jan; 21(1):132-40. PubMed ID: 16355282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonate therapy for osteogenesis imperfecta.
    Dwan K; Phillipi CA; Steiner RD; Basel D
    Cochrane Database Syst Rev; 2014 Jul; (7):CD005088. PubMed ID: 25054949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonate therapy for osteogenesis imperfecta.
    Dwan K; Phillipi CA; Steiner RD; Basel D
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD005088. PubMed ID: 27760454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in serum bone turnover markers and bone mineral density Z-score in children with osteogenesis imperfecta after zoledronic acid treatment.
    Jin J; Yue L; Lu Y; Zhen Z; Wu H; Shan X
    J Investig Med; 2024 Oct; 72(7):715-722. PubMed ID: 38715223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: a 2-year prospective observational study.
    Otaify GA; Aglan MS; Ibrahim MM; Elnashar M; El Banna RA; Temtamy SA
    Osteoporos Int; 2016 Jan; 27(1):81-92. PubMed ID: 26138583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate.
    Lindahl K; Kindmark A; Rubin CJ; Malmgren B; Grigelioniene G; Söderhäll S; Ljunggren Ö; Åström E
    Bone; 2016 Jun; 87():11-8. PubMed ID: 26957348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alendronate treatment in children with osteogenesis imperfecta.
    Akcay T; Turan S; Guran T; Bereket A
    Indian Pediatr; 2008 Feb; 45(2):105-9. PubMed ID: 18310788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.